Evicita · Supplement evidence, graded and cited · Supplements · Lifestyle · Mechanisms · Lab tests · 中文

Tauroursodeoxycholic acid (TUDCA)

Tauroursodeoxycholic Acid (TUDCA) · also known as TUDCA, Tauroursodeoxycholic acid

Tauroursodeoxycholic acid is an endogenous hydrophilic bile acid. Animal studies show it can reduce endoplasmic reticulum stress. A human trial at 1750 mg/day found only some insulin sensitivity measures improved, and ER stress markers in tissue showed no change.

Typical dose: The typical dose is 250–500 mg/day, which can be taken with meals. The results of the 1750 mg/day human trial cannot be directly applied to this dose.
Absorption and forms: After oral intake, it can enter the enterohepatic circulation and accumulate in bile. Taking it with a fatty meal is not required; there is currently no evidence that taking it with food works better.

Clinical uses and human evidence

Blood sugar and insulin resistance

Mixed resultsGrade C · Preliminary evidence
Studies (1)
  1. Kars 2010 · Diabetes · RCT · n=20 — Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women

Fatty liver and liver enzymes

Mixed resultsGrade C · Preliminary evidence
Studies (1)
  1. Ma 2016 · Medicine (Baltimore) · RCT · n=199 — A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis

Mechanisms of action

Chaperone relief of ER stress and improved bile acid flow

★★★☆☆Mechanism evidence: grade CPrimary target

TUDCA can reduce ER stress markers in diabetic mice and in cell studies. In a randomized trial of 20 people, 1750 mg/day improved some insulin sensitivity measures, but stress markers in muscle and fat tissue did not change, so a molecular chaperone effect in humans has not been confirmed.

References (2)
  1. Özcan et al. 2006 · Diabetic mouse and cell study: TUDCA reduced ER stress-related markers
  2. Kars et al. 2010 · 20-person RCT: 1750 mg/day improved some insulin sensitivity measures, and ER stress markers in muscle and fat tissue did not change

Epithelial tight junction (ZO-1 / Occludin) reinforcement and barrier repair

★★★☆☆Mechanism evidence: grade CSecondary target

Evidence for improved intestinal tight junctions comes mainly from mice on a high-fat diet and from colitis models. TUDCA can restore some tight junction-related gene expression and reduce the downregulation of ZO-1 and occludin. No reliable human study has directly measured tight junction proteins at routine oral doses.

References (2)
  1. High-fat diet mouse study 2018 · Animal study: TUDCA restored some intestinal tight junction-related gene expression
  2. Luo et al. 2024 · Mouse colitis model: TUDCA reduced the downregulation of ZO-1 and occludin

Safety and drug interactions

Contraindicated in complete mechanical obstruction of the common bile duct by stones. Use with caution during pregnancy.
Open in the interactive app ›